scholarly journals Reply to: “Established” Respiratory Treatment in ARDS: Scientific Rigor or a Square Peg in a Round Hole?

Author(s):  
C. Corey Hardin
1996 ◽  
Author(s):  
William W. Taylor ◽  
III
Keyword(s):  

Author(s):  
Philip C. Kendall ◽  
Jonathan S. Comer

This chapter describes methodological and design considerations central to the scientific evaluation of treatment efficacy and effectiveness. Matters of design, procedure, measurement, data analysis, and reporting are examined and discussed. The authors consider key concepts of controlled comparisons, random assignment, the use of treatment manuals, integrity and adherence checks, sample and setting selection, treatment transportability, handling missing data, assessing clinical significance, identifying mechanisms of change, and consolidated standards for communicating study findings to the scientific community. Examples from the treatment outcome literature are offered, and guidelines are suggested for conducting treatment evaluations that maximize both scientific rigor and clinical relevance.


2020 ◽  
pp. 002188632098271
Author(s):  
Denny Gioia

The Journal of Applied Behavioral Science is in the enviable position of being a go-to journal for many readers seeking useable insights for solving practical problems in managing modern organizations. A perennial source of such knowledge has been case studies, but case studies have been treated as questionable sources of widely applicable knowledge because they have been assumed to be idiosyncratic and to lack adequate “scientific” rigor. In this brief article, I argue for using a methodological approach to studying single cases that addresses both these thorny problems.


2021 ◽  
pp. 1-14
Author(s):  
Conor Fearon ◽  
Alfonso Fasano

Studies focusing on the relationship between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), coronavirus disease 2019 (COVID-19), and Parkinson’s disease (PD) have provided conflicting results. We review the literature to investigate: 1) Are PD patients at higher risk for contracting COVID-19 and are there specific contributing factors to that risk? 2) How does COVID-19 affect PD symptoms? 3) How does COVID-19 present in PD patients? 4) What are the outcomes in PD patients who contract COVID-19? 5) What is the impact of COVID-19 on PD care? 6) Does COVID-19 increase the risk of developing PD? A literature search was performed from 1979 to 2020 using the terms: ‘Parkinson’s disease’ and ‘parkinsonism’ combined with: ‘COVID-19’; ‘SARS-CoV-2’ and ‘coronavirus’. It does not appear that PD is a specific risk factor for COVID-19. There is evidence for direct/indirect effects of SARS-CoV-2 on motor/non-motor symptoms of PD. Although many PD patients present with typical COVID-19 symptoms, some present atypically with isolated worsening of parkinsonian symptoms, requiring increased anti-PD therapy and having worse outcomes. Mortality data on PD patients with COVID-19 is inconclusive (ranging from 5.2%to 100%). Patients with advanced PD appear to be particularly vulnerable. Single cases of acute hypokinetic-rigid syndrome have been described but no other convincing data has been reported. The rapidity with which COVID-19 has swept across the globe has favored the proliferation of studies which lack scientific rigor and the PD literature has not been immune. A coordinated effort is required to assimilate data and answer these questions in larger PD cohorts.


Sign in / Sign up

Export Citation Format

Share Document